286 filings
ARS
2023 FY
ITCI
Intra-Cellular Therapies Inc
29 Apr 24
Annual report to shareholders
4:48pm
DEFA14A
ITCI
Intra-Cellular Therapies Inc
29 Apr 24
Additional proxy soliciting materials
4:46pm
DEF 14A
ITCI
Intra-Cellular Therapies Inc
Definitive proxy
29 Apr 24
4:06pm
8-K
ITCI
Intra-Cellular Therapies Inc
24 Apr 24
Other Events
4:20pm
8-K
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Entry into a Material Definitive Agreement
5:25pm
424B5
n0j194jfd917iqxz7y2v
18 Apr 24
Prospectus supplement for primary offering
5:23pm
8-K
bnw692
16 Apr 24
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:40pm
424B5
yjiwhahs9iv26edudg5
16 Apr 24
Prospectus supplement for primary offering
4:37pm
S-3ASR
xurgke0c9 w8z
16 Apr 24
Automatic shelf registration
4:01pm
8-K
ds5ojy5xyhtmh ub
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
rke39qfb
1 Apr 24
Other Events
5:15pm
8-K
guolpn99f ozz358a
19 Mar 24
Intra-cellular Therapies Announces Executive Appointments and Leadership Changes
8:44am
8-K
mve7ypn
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
2cvdc us048o3ic6
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
teu8hh802mwg vzg
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
8-K
6h8y2y53ywkjk7l
23 Jun 23
Submission of Matters to a Vote of Security Holders
4:15pm